A postdoctoral research position is now available at Vanderbilt University in the area of cancer metastasis and drug delivery. The King Lab is focused on using native immune cells as carriers for anti-cancer therapeutics, to target disseminating tumor cells and prevent the lymphatic and bloodborne spread of cancer.
For more information on our research, see the following references:
Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc. Natl. Acad. Sci. U S A. 2014 111:930-5.
Chandrasekaran S, Chan MF, Li J, King MR. Super natural killer cells that target metastases in the tumor draining lymph nodes. Biomaterials. 2016 77:66-76.
Wayne EC, Chandrasekaran S, Mitchell MJ, Chan MF, Lee RE, Schaffer CB, King MR. TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer. J. Controlled Release. 2016 223:215-23.
To apply, send a CV, cover letter, and list of three references to Prof. Michael King at email@example.com. This work is funded by the National Institutes of Health.
Ph.D. applicants should be experienced in xenograft mouse models of cancer metastasis. Expertise in cancer immunotherapy and nanoparticle technology is welcome, but not required.
Additional Salary Information: Salary commensurate with experience, following NIH guidelines.
About Vanderbilt University Department of Biomedical Engineering
The King Lab works at the interface between Cellular Engineering, Drug Delivery, and Nanotechnology. We employ tools and concepts from engineering to understand biomedically important processes that occur in the bloodstream, including cancer metastasis, inflammation, and thrombosis. We have found that tumor cells in the circulation can mimic the physical mechanisms used by white blood cells to tra...ffic through the body and adhere to the blood vessel wall, and we have explored strategies to interrupt this metastasis process by targeting specific adhesion receptors. Microscale flow devices have been developed in our lab that recreate the complex microenvironment of the circulation where inflammation and cancer metastasis occur. We have invented new biomaterial surfaces based on natural halloysite nanotubes, that capture rare circulating tumor cells (CTCs) from blood while simultaneously repelling white blood cells. This nanotube-based flow system has gained attention since it can be easily adopted by clinical and biology labs and recreates the natural rolling process that CTCs follow in the body. The selectin adhesion receptors important in leukocyte, stem cell, and CTC trafficking have unique biophysics that make them ideal for targeted drug delivery. The King Lab has pioneered the use of selectin proteins to deliver apoptosis death signals to tumor cells in flowing blood, and to deliver therapeutic cargo (e.g., siRNA, chemotherapeutics) encapsulated in nanoscale liposomes.